CGM
ABBV icon

Capital Growth Management’s AbbVie ABBV Stock Holding History

Capital Growth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-155,000
Closed -$15.2M – 47
2020
Q2 		$15.2M Sell
155,000
-243,000
-61% -$21.4M 1.77% 26
2020
Q1 		$30.3M Buy
398,000
+333,000
+512% +$28.4M 4.26% 6
2019
Q4 		$5.75M Buy
+65,000
New +$5.4M 0.47% 39

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Capital Growth Management's ABBV Position: Q3 2020 in Review

Capital Growth Management sold out of AbbVie (ABBV) in Q3 2020, closing a stake of 155,000 shares — an estimated $15.2M sold.

Capital Growth Management first reported a position in ABBV in Q4 2019 and held it in 3 quarters. The position peaked at $30.3M in Q1 2020. 2,366 funds tracked by Wall St. Rank hold ABBV as of Q3 2020.

  • Capital Growth Management reported no remaining AbbVie position as of Q3 2020 after selling out during the quarter.
  • Capital Growth Management sold 155,000 AbbVie shares in Q3 2020, an estimated $15.2M.
  • Capital Growth Management first reported a position in AbbVie in Q4 2019 and held it in 3 quarters.
  • Capital Growth Management's AbbVie position peaked at $30.3M in Q1 2020.
  • 2,366 funds tracked by Wall St. Rank held AbbVie as of Q3 2020.

Based on Capital Growth Management's 13F filing for Q3 2020, filed 12 Nov 2020.